| T-vec (Herpes simplex virus type 1 oncolytic virus, Amgen)
|
Anti-CTLA-4 (ipilimumab, BMS) |
Melanoma |
NCT01740297 |
| Anti-PD-1 (pembrolizumab, Merck) |
Melanoma |
NCT02263508 |
| radiation |
STS |
NCT02453191 |
| DNX-2401 (Oncolytic adenovirus, DNAtrix)
|
IFNγ |
Glioblastoma |
NCT02197169 |
| HF10 (HSV1 oncolytic virus, Takara)
|
Anti-CTLA-4 (ipilimumab, BMS) |
Melanoma |
NCT02272855 |
| CAVATAK (Oncolytic Coxsackievirus A21, Viralytics)
|
Anti-CTLA-4 (ipilimumab, BMS) |
Melanoma |
NCT02307149 |
| BCG Mycobacterium bovis
|
Anti-CTLA-4 (ipilimumab, BMS) |
Melanoma |
NCT01838200 |
| Poly-ICLC (TLR7–8 agonist, Oncovir)
|
Flt3-Ligand (CDX-301, Celldex) |
B cell Lymphoma |
NCT01976585 |
| SD-101 (TLR9 agonist , Dynavax)
|
Anti-CTLA-4 (ipilimumab, BMS) |
B cell Lymphoma |
NCT02254772 |
| radiation |
B cell Lymphoma |
NCT02266147 |
